Recent News and Upcoming Events

Recent News

• July 8, 2020

  Aspira Women’s Health CEO Valerie Palmieri quoted in Forbes

  Valerie Palmieri, President and CEO of Aspira Women's Health, was quoted in an article on Forbes.com today, Wednesday, July 8, 2020. The article describes the gender gap which exists in healthcare today and the steps companies are taking to challenge the status quo through research, innovation, and disruptive technology. Read the full article here.

• July 1, 2020

  Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million

  For a pdf of this press release please click here AUSTIN, Texas, July 1, 2020 — Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have agreed to purchase approximately $11 million of unregistered shares…

• June 29, 2020

  Aspira Women’s Health, Inc. Announces First Patient Enrolled in Prospective OVANex Study for Benign Pelvic Mass Monitoring

  For a pdf of this press release please click here AUSTIN, Texas — June 29, 2020 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the first patient enrolled in a national clinical study of benign pelvic mass management. The study will enroll over 1,000 women for assessing ovarian cancer…

• June 11, 2020

  Vermillion, Inc. Announces Rebranding and Company Name Change to Aspira Women’s Health Inc.

  For a pdf of this press release please click here AUSTIN, Texas — June 11, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on ovarian cancer risk assessment, today announced a major rebranding to reflect the company’s continuing evolution towards becoming a comprehensive gynecologic health company, including a corporate name change…

• June 10, 2020

  Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment Biomarkers

  For a pdf of this press release please click here AUSTIN, Texas — June 10, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its wholly-owned subsidiary ASPIRA Labs has completed laboratory validation of the Roche Elecsys Anti-SARS-CoV-2 antibody test for detecting the presence…